Search Within

Kazunori Murata

Formats
  1. Journal Article (21)
  2. Meeting Abstract (8)
  3. Book Section (4)
Groups
  1. Department of Pathology and Laboratory Medicine (33)
  2. Department of Medicine (21)
  3. Hematologic Malignancies, Division of (20)
  4. Center for Hematologic Malignancies (19)
  5. Hematologic Malignancies Research (16)
  6. Myeloma (16)

More Groups

People
  1. Lakshmi Ramanathan (15)
  2. Carl Landgren (13)
  3. David Chung (12)
  4. Heather Landau (12)
  5. Sergio Giralt (12)
  6. Katie Thoren (11)

More People

Years
  1. 2025 (1)
  2. 2024 (2)
  3. 2022 (3)
  4. 2021 (7)
  5. 2020 (4)
  6. 2019 (4)

More Years

Publications
  1. Blood (7)
  2. Clinical Biochemistry (4)
  3. Blood Cancer Journal (2)
  4. Cancer Biomarkers: Clinical Aspects and Laboratory Determination (2)
  5. JAMA Oncology (2)
  6. Journal of Applied Laboratory Medicine (2)

More Publications

Publishers
  1. Elsevier Inc. (10)
  2. American Society of Hematology (8)
  3. Nature Publishing Group (3)
  4. Amer Assoc Clinical Chemistry (2)
  5. American Medical Association (2)
  6. Elsevier B.V. (1)

More Publishers

Results (33)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: A single-arm, single-centre, phase 2 trial
    Journal Article

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Pesticide use and kidney function among farmers in the Biomarkers of Exposure and Effect in Agriculture study
    Journal Article

    Shearer, J. J.; Sandler, D. P.; Andreotti, G.; Murata, K.; Shrestha, S.; Parks, C. G.; Liu, D.; Alavanja, M. C.; Landgren, O.; Beane Freeman, L. E.; more...
    Environmental Research (2021)

    Fulltext@MSK | Save
  • Lifetime pesticide use and monoclonal gammopathy of undetermined significance in a prospective cohort of male farmers
    Journal Article

    Hofmann, J. N.; Beane Freeman, L. E.; Murata, K.; Andreotti, G.; Shearer, J. J.; Thoren, K.; Ramanathan, L.; Parks, C. G.; Koutros, S.; Lerro, C. C.; more...
    Environmental Health Perspectives (2021)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in patients with multiple myeloma treated with continuous lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Diamond, B.; Korde, N.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Tan, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Improved quality of life with interleukin-6 (IL-6) blockade with siltuximab peri-autologous hematopoietic stem cell transplantation (AHCT) in older patients with multiple myeloma (MM)
    Meeting Abstract

    Shah, G. L.; Murata, K.; Holder, J.; Marcello, L.; Cho, S.; Hoover, E.; Chung, D. J.; Dahi, P. B.; Lahoud, O. B.; Scordo, M.; more...
    Biology of Blood and Marrow Transplantation (2020)

    Fulltext@MSK | Save
  • Identification of gamma heavy chain disease using MALDI-TOF mass spectrometry
    Journal Article

    Thoren, K. L.; Eveillard, M.; Chan, P.; Doddi, S.; Cho, S.; Murata, K.
    Clinical Biochemistry (2020)

    Fulltext@MSK | Save
  • Monoclonal gammopathies
    Book Section

    Murata, K.; McCash, S.; Landgren, C. O.
    In Rich, R. R.; Fleisher, T. A.; Shearer, W. T.; Schroeder, H. W. Jr; Frew, A. J.; Weyand, C. M (Eds.) Clinical Immunology: Principles and Practice. 5th ed (2019)

    Fulltext@MSK | Save
  • Long-term sustained minimal residual disease (MRD) negativity in multiple myeloma patients treated with lenalidomide maintenance therapy: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Mastey, D.; Lesokhin, A. M.; Smith, E. L.; Shah, U. A.; Mailankody, S.; Hultcrantz, M.; Hassoun, H.; Lu, S. X.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Smith, E. L.; Shah, U. A.; Lu, S. X.; Mastey, D.; Salcedo, M.; more...
    Blood (2019)

    Fulltext@MSK | Save